Embargo expired: 3/29/2012 7:00 AM EDT
Source Newsroom: Endocrine Society
New study emphasizes importance of reducing human exposure to
Newswise — Chevy Chase, MD— Endocrine-disrupting chemicals (EDCs)—such as BPA—can show tangible effects on health endpoints at high dosage levels, yet those effects do not predict how EDCs will affect the endocrine system at low doses, according to a recent study accepted for publication in The Endocrine Society’s Endocrine Reviews. Study authors say current definitions of low-dosage as used by the U.S. Environmental Protection Agency (EPA) do not fully take into account the unique influence that low doses of EDCs have on disease development in humans.
Endocrine-disrupting chemicals are substances in the environment that interfere with hormone biosynthesis, metabolism or action resulting in adverse developmental, reproductive, neurological and immune effects in both humans and wildlife. The current report found that low doses of EDCs, which are comparable to the average person’s environmental exposure to these chemicals, can result in significant health effects.
“Whether low doses of EDCs influence disorders in humans is no longer conjecture as epidemiological studies show that environmental exposures to EDCs are associated with human diseases and disabilities,” said Laura Vandenberg of Tufts University in Medford, Mass. and lead author of the study. “Current testing paradigms are missing important, sensitive endpoints and fundamental changes in chemical testing and safety determination are needed to protect human health.”
In this study, researchers reviewed the current EDC literature and explored the relationships between dose and effect. They found that this relationship could be non-linear; meaning that EDCs effect on the body varied within the range of doses examined. The report provides a detailed discussion on the mechanisms responsible for generating this phenomenon, plus hundreds of examples from the cell culture, animal and epidemiology literature.
“Low-dose effects are remarkably common in studies of natural hormones and EDCs,” said Vandenberg. “We recommend greatly expanded and generalized safety testing and surveillance to detect potential adverse effects of this broad class of chemicals. Before new chemicals are developed, a wider range of doses, extending into the low-dose range, should be fully tested.”
Other researchers working on the study include: Theo Colborn of The Endocrine Disruption Exchange in Paonia, Colo.; Tyrone Hayes of the University of California, Berkeley; Jerrold Heindel of the National Institute of Environmental Health Sciences in Research Triangle Park, N.C.; David Jacobs of the University of Minnesota in Minneapolis; Duk Hee Lee of Kyungpook National University in Daegu, South Korea; Toshi Shioda of Massachusetts General Hospital Center for Cancer Research in Charlestown; Ana Soto of Tufts University School of Medicine; Frederick vom Saal and Wade Welshons of the University of Missouri-Columbia; R. Thomas Zoeller of the University of Massachusetts-Amherst; and John Peterson Myers of Environmental Health Sciences in Charlottesville, Va.
The article, “Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses,” appears in the June 2012 issue of Endocrine Reviews.
# # #
Founded in 1916, The Endocrine Society is the world’s oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society’s membership consists of over 15,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at www.endo-society.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.